When analysing RCTs comparing SGLT2-i with other OAD, seven patients allocated to canagliflozin and three allocated to sitagliptin were diagnosed with other types of cancer than bladder or breast cancer (2.41, 0.69 to 8.37; 2 RCTs). Here, SLC5A2 is linked to cancer.